scholarly journals Effects of Composite Supplement Containing Astaxanthin and Sesamin on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial

2019 ◽  
Vol 68 (2) ◽  
pp. 839-839
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Functions ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment

2008 ◽  
Vol 22 (1) ◽  
pp. 21-29 ◽  
Author(s):  
Teresa Gómez-Isla ◽  
Rafael Blesa ◽  
Merce Boada ◽  
Jordi Clarimón ◽  
Teodoro Del Ser ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Yan Press ◽  
Boris Punchik ◽  
Ella Kagan ◽  
Alexander Berzak ◽  
Tamar Freud ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Adverse Events ◽  
Verbal Memory ◽  
Cognitive Assessment ◽  
Controlled Trial ◽  
Immediate Release ◽  
Cognitive Outcome ◽  
Double Blind ◽  
Double Blind Placebo

Background: To evaluate the efficacy, safety and tolerability of methylphenidate (MPH) for cognitive function in older patients with mild cognitive impairment (MCI).Methods: Male and female subjects aged 65 years and older with a clinical diagnosis MCI were included in an exploratory randomized, double-blind, placebo-controlled trial. Eligible subjects were assigned to either treatment with immediate-release MPH or placebo. The active compound was administered in an increasing-dose stepwise fashion, namely 10 mg MPH on day 1, 20 mg on day 2, and 30 mg on day 3. Subjects remained under observation for 4 h following drug administration and were monitored for changes in blood pressure and for adverse events. Cognitive outcome measures included the Montreal Cognitive Assessment (MoCA) and the Neurotrax Mindstreams computerized cognitive assessment battery.Results: Of 17 subjects enrolled, 15 subjects completed the study, 7 in the active MPH group and 8 in the placebo group. The average age of the participants was 76.1 ± 6.6 years and 10 (66.7%) were men. Following the final dose a significant benefit on memory (predominantly non-verbal memory) was found in the MPH group. While 12 adverse events were reported, they were all rated as mild to moderate.Conclusions: Our finding of modest beneficial effects of MPH on memory tests in older subjects with MCI in this exploratory study is of interest and should be investigated in further studies.

P3-462: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment

2006 ◽  
Vol 2 ◽  
pp. S512-S512 ◽  
Author(s):  
Teresa Gomez-Isla ◽  
Genı́s Muñoz ◽  
Jose M. Ferro ◽  
José Manuel Martı́nez Lage ◽  
José Carlos Navas Ramı́rez
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document